"Cytarabine" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant properties. (From Martindale, The Extra Pharmacopoeia, 30th ed, p472)
Descriptor ID |
D003561
|
MeSH Number(s) |
D03.383.742.680.245.453 D13.570.065.300 D13.570.685.245.453
|
Concept/Terms |
Cytarabine- Cytarabine
- Arabinofuranosylcytosine
- Aracytidine
- Cytosine Arabinoside
- Arabinoside, Cytosine
- Arabinosylcytosine
Cytosar- Cytosar
- Cytosar-U
- Cytosar U
- CytosarU
|
Below are MeSH descriptors whose meaning is more general than "Cytarabine".
Below are MeSH descriptors whose meaning is more specific than "Cytarabine".
This graph shows the total number of publications written about "Cytarabine" by people in this website by year, and whether "Cytarabine" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1994 | 0 | 1 | 1 |
1996 | 0 | 1 | 1 |
2004 | 0 | 1 | 1 |
2005 | 0 | 1 | 1 |
2022 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Cytarabine" by people in Profiles.
-
Clofarabine increases the eradication of minimal residual disease of primary B-precursor acute lymphoblastic leukemia compared to high-dose cytarabine without improvement of outcome. Results from the randomized clinical trial 08-09 of the Cooperative Acute Lymphoblastic Leukemia Study Group. Haematologica. 2022 05 01; 107(5):1026-1033.
-
Use of MLL/GRAF fusion mRNA for measurement of minimal residual disease during chemotherapy in an infant with acute monoblastic leukemia (AML-M5). Genes Chromosomes Cancer. 2005 Aug; 43(4):424-6.
-
ERK signaling pathway is differentially involved in erythroid differentiation of K562 cells depending on time and the inducing agent. Cell Biol Int. 2004; 28(5):403-10.
-
Incidence and clinical outcome of children with BCR/ABL-positive acute lymphoblastic leukemia (ALL). A prospective RT-PCR study based on 673 patients enrolled in the German pediatric multicenter therapy trials ALL-BFM-90 and CoALL-05-92. Leukemia. 1996 Jun; 10(6):957-63.
-
Poor prognosis of prethymic phenotype acute lymphoblastic leukemia (pre-T-ALL). Leukemia. 1994 Aug; 8(8):1406-8.